Key Takeaways from Agenus' Earnings Report

Shares of biotech Agenus (Nasdaq: AGEN  ) appreciated almost 5% today, after the company posted its 3rd quarter earnings. The company's key compound, QS-21 Stimulon, is licensed to some of the biggest players in the pharmaceutical space, ,including GlaxoSmithKline (NYSE: GSK  ) and Janssen, which is a subsidiary of Johnson & Johnson (NYSE: JNJ  ) .

In the following video, health care analysts Max Macaluso and David Williamson discuss the company's latest quarter and a few things Agenus investors should watch.

 

Biotech companies can be some of the most exciting-and riskiest-investments on the market. However, it's essential to balance speculative plays in your portfolio with stocks that can help you build long-term weatlh. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you retire well, and also include some winning wealth-building strategies that every investor should know. Click here now to keep reading.

 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2077980, ~/Articles/ArticleHandler.aspx, 9/17/2014 1:58:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement